Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.3752W HIGH $21.73
Volume
2.66 M
Value Traded
15.56 M
Short % Float
10.67%
-8.2%Week
-27.86%1 Month
-44.48%3 Month
-51.67%6 Month
-4.49%5 Year
-62.58%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
683.76 M
EPS (TTM)
-1.03
P/E Ratio
-
Ent. Value
193.16 M
Total Shares
197.05 M
Float Shares
165.30 M
Insiders
16.11%
Institutions
83.69%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
WVE Catalyst Timeline
Dated clinical, regulatory and corporate events for Wave Life Sciences Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Wave Life Sciences Ltd.
832Total events
14Upcoming
188Tier-1 (high impact)
2016 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲FDA Feedback ReceivedWVE-006FDA Meeting
FDA feedback supports registrational pathway for WVE-006 in AATD
alpha-1 antitrypsin deficiency (AATD)source ↗
▲Development Candidate NominationPreclinical
GSK selects SpiNA design GalNAc-siRNA candidate for hepatology indication to transition into GSK's development pipeline
hepatologysource ↗
▲Milestone PaymentCorporate
Wave to receive $12 million milestone payment for GSK's candidate selection
hepatologysource ↗
●Trial InitiationWVE-007FiledTrial
Wave initiates Phase 2a combination trial of WVE-007 with tirzepatide in obesity
obesitysource ↗
●Management ChangeCorporate
Monika Vnuk, MD appointed Chief Business Officer of Wave Life Sciences
●Equity OfferingCorporate
Dr. Vnuk granted stock option for 375,000 shares at $4.25 per share
●Other Regulator MilestoneEx-US Regulatory
Redomiciliation to Delaware expected to become effective
◆FDA ApprovalWVE-006FDA Decision
FDA meeting on potential accelerated approval pathway
alpha-1 antitrypsin deficiencysource ↗
▲First Patient DosedWVE-007FiledTrial
Dosing underway in Phase 2a multidose portion of INLIGHT trial
obesitysource ↗
▲Enrollment CompleteWVE-006Trial
Cohorts fully enrolled and dosing complete
alpha-1 antitrypsin deficiencysource ↗
◆Other Regulator MilestoneEx-US Regulatory
Singapore Court hearing to approve Scheme of Arrangement for redomiciliation
▲Trial InitiationWVE-007FiledTrial
Initiate additional Phase 2 trials in combination with incretins and as post-incretin maintenance
obesitysource ↗
▲Topline ReadoutWVE-007FiledClinical Data
Phase 1 data at six months follow-up showed visceral fat reduction
obesitysource ↗
◆FDA Feedback ReceivedWVE-006FDA Meeting
Feedback on potential accelerated approval pathway for WVE-006 anticipated mid-2026
AATDsource ↗
◆Accelerated Approval PathwayWVE-006Designation
Wave plans to engage FDA on potential accelerated approval pathway for WVE-006
alpha-1 antitrypsin deficiency (AATD)source ↗
◆Poster PresentationWVE-008Presentation
Poster presentation at EASL Congress on preclinical data for WVE-008
PNPLA3 I148M liver diseasesource ↗
◆Oral PresentationPresentation
CEO Paul Bolno to participate in fireside chat at 2026 RBC Capital Markets Global Healthcare Conference
◆Oral PresentationWVE-006Presentation
Late-breaking oral presentation of RestorAATion-2 data at ATS 2026
alpha-1 antitrypsin deficiencysource ↗
▲Topline ReadoutWVE-006Clinical Data
Updated data from RestorAATion-2 trial announced
alpha-1 antitrypsin deficiencysource ↗
●Quarterly UpdateWVE-006Corporate
Investor conference call and webcast to review RestorAATion-2 data
alpha-1 antitrypsin deficiency (AATD)source ↗
◆Poster PresentationWVE-008Presentation
Poster presentation of preclinical data at EASL Congress
PNPLA3 I148M liver diseasesource ↗
◆Management ChangeCorporate
Singapore High Court hearing on application to convene shareholder meeting for redomiciliation
◆Other Regulator MilestoneEx-US Regulatory
Singapore High Court hearing on application to convene shareholder meeting for redomiciliation
▲FDA Filing AcceptedWVE-007FiledRegulatory Filing
FDA acceptance of Phase 2a multidose portion of INLIGHT trial of WVE-007
obesitysource ↗
◆Management ChangeCorporate
Deadline for written submissions or bundle of authorities to Singapore High Court
◆Management ChangeCorporate
Deadline for affidavits in response to Singapore High Court application
●Quarterly UpdateCorporate
Preliminary proxy materials filed with SEC for shareholder meeting
◆Timing GuidanceWVE-006Presentation
Regulatory feedback on accelerated approval pathway expected mid-2026
alpha-1 antitrypsin deficiencysource ↗
◆Trial InitiationWVE-007FiledTrial
Initiation of Phase 2a multidose portion of INLIGHT in individuals with higher BMI and comorbidities
obesitysource ↗
◆Topline ReadoutWVE-007FiledClinical Data
Three-month follow-up data from 600 mg single-dose cohort in Q2 2026
obesitysource ↗
◆FDA Feedback ReceivedWVE-006FDA Meeting
FDA feedback on potential accelerated approval pathway
alpha-1 antitrypsin deficiency (AATD)source ↗
◆Accelerated Approval PathwayWVE-006Designation
Regulatory feedback on potential accelerated approval pathway for WVE-006 expected mid-2026
alpha-1 antitrypsin deficiencysource ↗
▼Topline ReadoutWVE-007FiledClinical Data
Interim Phase 1 clinical data for WVE-007 announced
obesitysource ↗
▲Interim AnalysisWVE-007FiledTrial
Positive interim Phase 1 data from INLIGHT trial of WVE-007
overweight or obesitysource ↗
●Oral PresentationPresentation
Investor conference call and webcast to review INLIGHT Phase 1 interim clinical data
◆Timing GuidanceWVE-007FiledPresentation
Data from INLIGHT trial of WVE-007 expected this month (March 2026)
obesitysource ↗
◆Topline ReadoutWVE-007FiledClinical Data
Data from INLIGHT trial of WVE-007 expected this month
obesitysource ↗
▲Interim AnalysisWVE-007FiledTrial
Interim results from Phase 1 SAD portion of INLIGHT
obesitysource ↗
●Quarterly UpdateCorporate
Q4 and full year 2025 financial results webcast and conference call
●Oral PresentationPresentation
CEO Paul Bolno to participate in fireside chat at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Past FDA Catalysts and PDUFA Decisions
How WVE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | WVE-007 (INHBE GalNAc-siRNA) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C47 / 100
Pipeline Score
$118M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.2x
rNPV / MCap
Top 25%
Micro Cap(rank 165 of 658)
Percentile Rank
Wave Life Sciences Ltd. carries a moderate pipeline score (47/100), with $296M risk-adjusted pipeline value, led by WVE-N531 in Duchenne Muscular Dystrophy (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WVE-N531 Small moleculeNCT07209332 | Duchenne Muscular Dystrophy | Phase 2 | ENROLLING BY_INVITATION | 201 | Mar 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every WVE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| WVE-007 | Obesity and Cardiometabolic Diseases | Phase 1 | 2026-06-24 | visceral fat reduction: -14%; total fat reduction: -5%; waist circumference reduction: -3%Read More | Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic DiseasesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rawcliffe AdrianDirector | Sell | -12,700 | $5.29 | 08/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in WVE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1.4 % (-33.3 %) | 156.73 M | 26.98 M |
WVE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How WVE ranks across every disease it competes in
Competitive Position is a premium feature
See how WVE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialWVE News
WVEWave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Wave Life Sciences has received FDA feedback that supports a registrational pathway for WVE-006, an RNA editing treatment for alpha-1 antitrypsin deficiency (AATD). The company plans a two-year trial with a one-year interim analysis for potential accelerated approval. WVE-006 aims to provide a new standard-of-care for AATD patients, addressing both lung and liver issues.
Read more →WVEWave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Wave Life Sciences announced that GSK has selected a candidate for a hepatology indication to transition into its development pipeline. This selection triggers a $12 million milestone payment to Wave, which is also eligible for up to $375 million in additional milestones. The collaboration continues with three more programs advancing towards candidate selection.
Read more →WVE▼ -9.2%on this news
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Wave Life Sciences has initiated a Phase 2a trial for WVE-007, a GalNAc-siRNA, in combination with tirzepatide for obesity treatment. This trial aims to evaluate the effectiveness of WVE-007 in preventing weight regain after incretin cessation. The company is also planning to assess WVE-007 as a maintenance therapy in the future.
Read more →WVEWave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Wave Life Sciences has appointed Dr. Monika Vnuk as Chief Business Officer, bringing extensive experience from Sanofi, Blackstone, and Pfizer. Dr. Vnuk will lead business and corporate development efforts as Wave advances its RNA medicines pipeline. Her appointment is expected to drive growth and enhance strategic partnerships.
Read more →WVEWave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Wave Life Sciences Ltd. will present at the Cantor 2026 Global Healthcare Conference. CEO Paul Bolno is scheduled for a fireside chat on September 10, 2026. The event will be accessible via a live webcast, with a replay available afterward. Wave continues to advance its RNA medicines platform targeting various diseases.
Read more →WVEWave Life Sciences Announces Completion of Redomiciliation to Delaware
Wave Life Sciences has successfully completed its redomiciliation from Singapore to Delaware, effective August 7, 2026. This transition involved exchanging shares on a one-for-one basis for newly issued common stock in the Delaware corporation. The company expects no significant impact on its operations or workforce due to this change.
Read more →WVEWave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
Wave Life Sciences Ltd. has announced the expected completion date for its redomiciliation to the United States, following shareholder approvals and a court order in Singapore. The redomiciliation is set to become effective on August 7, 2026, after which the company will file necessary documents with the SEC. This move aims to enhance Wave's operational capabilities in RNA medicines.
Read more →WVEWave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences Ltd. announced its participation in two investor conferences in August 2026. CEO Paul Bolno will lead analyst-led fireside chats at both the BofA Securities SMID Cap Executive Insights Event and the Canaccord Genuity Annual Growth Conference. Live webcasts will be available, with replays archived on the company's website.
Read more →WVEWave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences reported its Q2 2026 financial results, highlighting the initiation of dosing in the Phase 2a trial of WVE-007 for obesity. The company is also preparing for an FDA meeting regarding accelerated approval for WVE-006, aimed at treating alpha-1 antitrypsin deficiency. Despite a significant cash position, the company reported a net loss of $69.4 million, reflecting increased research and development expenses.
Read more →WVEWave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
Wave Life Sciences Ltd. will host a live webcast and conference call on July 30, 2026, to discuss its second quarter financial results and provide business updates. The event will be accessible via the company's investor relations website. Wave focuses on RNA medicines and has a diverse pipeline addressing multiple health conditions.
Read more →WVEWave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
Wave Life Sciences Ltd. has received shareholder approval for its proposed redomiciliation to the United States. The Singapore Court is set to hear the application for the Scheme of Arrangement on July 14, 2026. This move aims to enhance the company's operational capabilities and align its corporate structure with its business strategy in RNA medicines.
Read more →WVEWave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
Wave Life Sciences has initiated the Phase 2a portion of the INLIGHT trial for WVE-007, targeting obesity and related cardiometabolic conditions. The trial will assess multiple outcomes, including body composition and metabolic health in individuals with higher BMI. Early Phase 1 results indicate significant reductions in visceral fat with a favorable safety profile, supporting further development of WVE-007.
Read more →WVE▼ -5.5%on this newsshared move
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Wave Life Sciences announced positive results from the RestorAATion-2 trial for WVE-006, an RNA editing oligonucleotide for alpha-1 antitrypsin deficiency. The trial showed significant reductions in harmful Z-AAT proteins and substantial increases in protective M-AAT levels. Safety data indicated no liver toxicities and a favorable response to infrequent subcutaneous dosing. Wave Life Sciences is on track to seek FDA feedback for accelerated approval in mid-2026.
Read more →WVEWave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
Wave Life Sciences Ltd. announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference in New York City on May 20, 2026. The event will be accessible via a live webcast, with a replay available afterward. Wave Life Sciences focuses on RNA medicines and has a diverse pipeline addressing various diseases.
Read more →WVE▲ +8.4%on this news
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences reported its Q1 2026 financial results, highlighting progress in its clinical trials, particularly for WVE-007 and WVE-006. The FDA has accepted the Phase 2a trial for WVE-007, which targets obesity, while data from the RestorAATion-2 trial for WVE-006 will be presented at an upcoming conference. The company remains well-capitalized with substantial cash reserves.
Read more →WVEWave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
Wave Life Sciences Ltd. will host a live webcast and conference call on April 28, 2026, to discuss its first quarter 2026 financial results and provide business updates. The event will be accessible via the company's investor relations website. Wave is known for its RNA medicines platform and has a diverse pipeline targeting several diseases.
Read more →WVEWave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
Wave Life Sciences is seeking approval for a redomiciliation from Singapore to the U.S. The Singapore High Court will hear the application on April 29, 2026. This move aims to enhance operational capabilities and shareholder value, but it remains subject to shareholder and court approval.
Read more →WVEWave Life Sciences Announces Proposed Redomiciliation to the United States
Wave Life Sciences has announced a plan to redomicile its parent company from Singapore to the United States, aiming to enhance operational efficiency and shareholder value. The move is expected to streamline regulatory compliance and reduce costs, aligning the company's domicile with its existing U.S. operations. The redomiciliation is subject to shareholder and court approvals, with expectations for completion in mid-2026.
Read more →About Wave Life Sciences Ltd.
Headquarters7 STRAITS VIEW, SINGAPORE, U0, 018936
BIOPHARMAWATCH ELITE PLUS
Trade the next WVE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime